Clinical Trials Logo

Recurrent Glioma clinical trials

View clinical trials related to Recurrent Glioma.

Filter by:

NCT ID: NCT06397560 Not yet recruiting - Glioma Clinical Trials

PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

POPCORN
Start date: June 2024
Phase: N/A
Study type: Interventional

The purpose of this research study is to see if a specific type of radiation therapy, called "proton pulsed reduced dose rate" or "PRDR radiotherapy" has any benefits at dose levels and number of fractions thought to be acceptable in earlier research studies. The researchers want to find out what effects (good and bad) PRDR has on people with cancer in the brain called a "recurrent high-grade glioma" meaning that it grows fast, can spread quickly, and it has come back or gotten worse after being treated previously.

NCT ID: NCT05676489 Not yet recruiting - Healthy Volunteers Clinical Trials

MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors

Start date: December 30, 2024
Phase: Early Phase 1
Study type: Interventional

This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-[F-18]fluoro-2-methyl-2-(methylamino)propanoic acid ([F-18]MeFAMP), for positron emission tomography (PET) imaging of primary and metastatic brain tumors. This study will include 3 cohorts: healthy volunteers for whole body dosimetry estimates (n=6-8, Dosimetry Cohort), patients undergoing evaluation for recurrent high grade glioma after radiation therapy (n=10, high grade glioma (HGG) Cohort), and patients with brain metastases from extra-cranial solid tumors before and after radiation therapy (n=10, Metastasis Cohort). Exploratory assessment of the diagnostic accuracy of MeFAMP for distinguishing recurrent/progressive brain tumors from radiation-related treatment effects will also be performed for subsequent trial design. The study will complete accrual and safety assessment in the Dosimetry Cohort before recruiting for the HGG and Metastasis Cohorts.

NCT ID: NCT05660369 Recruiting - Glioblastoma Clinical Trials

CARv3-TEAM-E T Cells in Glioblastoma

Start date: March 22, 2023
Phase: Phase 1
Study type: Interventional

The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).

NCT ID: NCT05611645 Active, not recruiting - Glioma Clinical Trials

Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence

Start date: October 1, 2022
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well lose dose bevacizumab with Hypofractionated Stereotactic Radiotherapy (HSRT) works versus bevacizumab alone in treating patients with glioblastoma at first recurrence. The primary endpoint is 6-month progress-free survivaloverall survival after the treatment. Secondary endpoints included overall survival, objective response rate, cognitive function, quality of life and toxicity.

NCT ID: NCT05406700 Recruiting - Glioma, Malignant Clinical Trials

Niraparib In Recurrent IDH 1/2 Gliomas

Start date: May 18, 2023
Phase: Early Phase 1
Study type: Interventional

This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. - This research study involves an experimental treatment called Niraparib.

NCT ID: NCT05297864 Terminated - Clinical trials for Recurrent Glioblastoma

PARP Inhibition for Gliomas (PI-4G or π4g)

OU-SCC-PI-4G
Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.

NCT ID: NCT05045027 Recruiting - Glioma Clinical Trials

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

Start date: September 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.

NCT ID: NCT04943718 Recruiting - Malignant Glioma Clinical Trials

Personalized Vaccine for Patients With Recurrent Malignant Glioma

Start date: July 15, 2021
Phase: Phase 1
Study type: Interventional

A single-arm, single-center, open-labeled study will be conducted with an aim to investigate the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent malignant glioma.

NCT ID: NCT04794972 Recruiting - Solid Tumor Clinical Trials

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Start date: April 14, 2021
Phase: Phase 1
Study type: Interventional

In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.

NCT ID: NCT04740190 Recruiting - Clinical trials for Recurrent Glioblastoma

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

TAC-GReD
Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma. Carboplatin will be added to sensitize the tumor to PARP inhibition, and low dose radiation therapy will be applied to increase talazoparib drug penetration through blood-brain barrier. The goal is to estimate the effect size of such combinational treatment approach in recurrent high-grade glioma with DNA damage repair deficiency (dDDR)